ALB and neoplasm: In the study realised by Guo et al. in 2022, it was found that paclitaxel administered in the form of albumin-paclitaxel nanoparticles, nab-paclitaxel, has a higher anti-tumour effect and a lower incidence of drug resistance, thereby increasing the survival of patients with breast cancer, but on the other hand, it also has a higher incidence of neurotoxic symptoms compared to standard paclitaxel.